HY 0004
Alternative Names: HY-0004Latest Information Update: 25 Aug 2023
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 24 Jul 2023 Early research in Cancer in China (unspecified route) (Sichuan Huiyu Pharmaceutical pipeline, July 2023)
- 24 Jul 2023 Early research in Cancer in Europe (unspecified route) (Sichuan Huiyu Pharmaceutical pipeline, July 2023)